The prognosis of patients with advanced cancers remains poor and calls for improved treatments. TheraPPI wants to offer a better prognosis to those patients by developing drugs modifying protein interactions.
TheraPPI's drug against advanced cancers already has solid efficacy data in animals and plans to enter into clinical development in less than 2 years. The vision for TheraPPI is that of a major biotech player with innovative drugs against severe diseases.